JONES DAY TALKS®: Real Assets Roundup Episode 2: A First Look at Data Centers: The Fourth Utility
LathamTECH in Focus: Tech Deals: The Emerging Focus of FDI Regulators?
LathamTECH in Focus: Navigating National Security: The Impact of FDI Reviews on Tech M&A
Compliance Tip of the Day: Rethinking Corporate AI Governance Through Design Intelligence
Maryland's Sales Tax on IT and Data Services
Sunday Book Review: July 20, 2025, The Best Books on Business Edition
(Podcast) The Briefing: Anthropic, Copyright, and the Fair Use Divide
The Briefing: Anthropic, Copyright, and the Fair Use Divide
SkadBytes Podcast | Tech’s Shifting Landscape: Five Trends Shaping the Conversation
No Password Required: From AOL to Award-Winning Cuisine to High-Stakes Hacking
The Authenticity Advantage: How Runbin Dong’s Scale Social AI Helps Small Businesses Shine
#Risk New York Speaker Series – Bridging the Gap: Effective Risk Communication in Compliance with Rob Clark, Jr.
Hsu Untied interview with Brad Waugh, General Counsel at TP-Link
Risk New York Speaker Series: AI Investments and Political Uncertainty with Chris Mason
#Risk New York Speaker Series: Exploring AI Risks in Compliance with Gwen Hassan
Unexpected Paths to IP Law with Dan Young and Colin White
Compliance Needs are Alive and Well: FTC's Recent Enforcement Activity
Innovation in Compliance: The Critical Importance of Mobile Application Security: Insights from Subho Halder
The LathamTECH Podcast — Getting Deals Done: Tackling Antitrust Challenges in Tech M&A
Compliance into the Weeds: Autonomous AI Whistleblowing Misconduct
Partnerships between the government and private companies are key drivers of innovation. A study of U.S. patents from 1982 to 2012 found collaborations with the federal government produce more “disruptive” inventions than...more
The new year marks the transition from the Biden administration and its whole-of-government approach to antitrust enforcement, to the return of President Trump. To spearhead his administration’s antitrust enforcement efforts,...more
• Masked by the recent high-profile drug pricing debate has been the Trump Administration's discussions about the development, approval and reimbursement of medical devices. Recent comments by Administration leaders, as well...more